We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA/EMA Strategic Plan Recommends Approaches to Pediatric Gaucher Drug Development
FDA/EMA Strategic Plan Recommends Approaches to Pediatric Gaucher Drug Development
Investigators looking to develop new therapies for children with Gaucher disease may use either multi-company, multi-arm clinical trials or data extrapolation techniques, according the FDA and European Medicines Agency.